Charles Newton's Insider Trades & SAST Disclosures
Charles Newton's most recent trade in 2seventy bio Inc was a trade of 33,400 Stock Options (Right to buy) done . Disclosure was reported to the exchange on May 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Charles Newton.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 2seventy bio Inc | Charles W. Newton | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 May 2025 | 33,400 | 0 | - | - | Stock Options (Right to buy) | |
| 2seventy bio Inc | Charles W. Newton | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 May 2025 | 17,092 | 5,533 | - | - | Common Stock | |
| 2seventy bio Inc | Charles W. Newton | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 May 2025 | 12,050 | 0 | - | - | Stock Options (Right to buy) | |
| 2seventy bio Inc | Charles W. Newton | Director | 13 May 2025 | 5,533 | 0 | - | - | Common Stock | ||
| Lyell Immunopharma Inc | Charles Newton W. | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.56 per share. | 17 Mar 2025 | 200,000 | 200,000 | - | 0.6 | 111,620 | Common Stock |
| Lyell Immunopharma Inc | Charles Newton W. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 450,000 | 450,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Charles Newton W. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 112,500 | 172,725 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Newton Charles W. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 56,250 | 56,250 | - | - | Option (right to buy) | |
| 2seventy bio Inc | Charles Newton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 12,050 | 12,050 | - | - | Stock Options (Right to buy) | |
| 2seventy bio Inc | Charles Newton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 6,025 | 22,625 | - | 0 | Common Stock | |
| Coherus Biosciences Inc | Charles Newton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 112,000 | 112,000 | - | - | Stock Option (Right to Buy) | |
| 2seventy bio Inc | Charles Newton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 33,400 | 33,400 | - | - | Stock Options (Right to buy) | |
| 2seventy bio Inc | Charles Newton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 16,600 | 16,600 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Charles Newton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Lyell Immunopharma Inc | Charles Newton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 40,000 | 48,729 | - | 0 | Common Stock | |
| Coherus Biosciences Inc | Charles Newton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 38,250 | 38,250 | - | - | Stock Option (Right to Buy) | |
| Lyell Immunopharma Inc | Charles Newton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 700,000 | 700,000 | - | - | Option (right to buy) | |
| Coherus Biosciences Inc | Charles Newton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 54,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
| Lyell Immunopharma Inc | Charles Newton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 500,000 | 500,000 | - | - | Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges